CLINICAL TRIALS PROFILE FOR METHICILLIN SODIUM

All Clinical Trials for METHICILLIN SODIUM

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00179959 ↗	The Impact of Treating Staphylococcus Aureus Infection and Colonization on the Clinical Severity of Atopic Dermatitis	Completed	Johnson & Johnson	Phase 4	2005-09-01	Staphylococcus aureus (S. aureus) infection is perceived not only as a common secondary complication of atopic dermatitis (AD), but also as a culprit in the worsening of this condition. In addition, the recent development of community acquired methicillin-resistant S. aureus (CA-MRSA) has presented a new challenge to our management of AD, both in treatment of acute infections and maintenance therapy. The investigators would like to perform a randomized investigator-blinded placebo-controlled study of children aged 6 months to 17 years with moderate to severe atopic dermatitis with clinical signs of secondary bacterial infection to study: 1) the prevalence of CA-MRSA in our patient population; 2) the relationship of sensitivity of the S. aureus organism cultured from the infected lesion(s) to clinical response to oral cephalexin therapy and severity of the AD; and 3) whether concurrent treatment of S. aureus infection initially with nasal mupirocin ointment and sodium hypochlorite (bleach) baths can result in long-term S. aureus eradication and clinical stability.
NCT00179959 ↗	The Impact of Treating Staphylococcus Aureus Infection and Colonization on the Clinical Severity of Atopic Dermatitis	Completed	Society for Pediatric Dermatology	Phase 4	2005-09-01	Staphylococcus aureus (S. aureus) infection is perceived not only as a common secondary complication of atopic dermatitis (AD), but also as a culprit in the worsening of this condition. In addition, the recent development of community acquired methicillin-resistant S. aureus (CA-MRSA) has presented a new challenge to our management of AD, both in treatment of acute infections and maintenance therapy. The investigators would like to perform a randomized investigator-blinded placebo-controlled study of children aged 6 months to 17 years with moderate to severe atopic dermatitis with clinical signs of secondary bacterial infection to study: 1) the prevalence of CA-MRSA in our patient population; 2) the relationship of sensitivity of the S. aureus organism cultured from the infected lesion(s) to clinical response to oral cephalexin therapy and severity of the AD; and 3) whether concurrent treatment of S. aureus infection initially with nasal mupirocin ointment and sodium hypochlorite (bleach) baths can result in long-term S. aureus eradication and clinical stability.
NCT00179959 ↗	The Impact of Treating Staphylococcus Aureus Infection and Colonization on the Clinical Severity of Atopic Dermatitis	Completed	Northwestern University	Phase 4	2005-09-01	Staphylococcus aureus (S. aureus) infection is perceived not only as a common secondary complication of atopic dermatitis (AD), but also as a culprit in the worsening of this condition. In addition, the recent development of community acquired methicillin-resistant S. aureus (CA-MRSA) has presented a new challenge to our management of AD, both in treatment of acute infections and maintenance therapy. The investigators would like to perform a randomized investigator-blinded placebo-controlled study of children aged 6 months to 17 years with moderate to severe atopic dermatitis with clinical signs of secondary bacterial infection to study: 1) the prevalence of CA-MRSA in our patient population; 2) the relationship of sensitivity of the S. aureus organism cultured from the infected lesion(s) to clinical response to oral cephalexin therapy and severity of the AD; and 3) whether concurrent treatment of S. aureus infection initially with nasal mupirocin ointment and sodium hypochlorite (bleach) baths can result in long-term S. aureus eradication and clinical stability.
NCT01577524 ↗	The Use of Diluted Povidone Iodine Irrigation in Spine Surgery	Terminated	Attabib, Najmedden, M.D.	Phase 2	2012-01-01	The purpose of the study is to determine whether diluted Povidone Iodine solution used to irrigate surgical wounds during spine surgery decreases the incidence of surgical site infections.

Clinical Trial Conditions for METHICILLIN SODIUM

Condition Name

Condition Name for METHICILLIN SODIUM
Intervention	Trials
Atopic Dermatitis	1
Atrial Fibrillation	1
Surgical Site Infection	1

Condition MeSH

Condition MeSH for METHICILLIN SODIUM
Intervention	Trials
Eczema	1
Dermatitis, Atopic	1
Dermatitis	1
Atrial Fibrillation	1

Clinical Trial Locations for METHICILLIN SODIUM

Trials by Country

Trials by Country for METHICILLIN SODIUM
Location	Trials
Canada	1
United States	1
Brazil	1

Trials by US State

Trials by US State for METHICILLIN SODIUM
Location	Trials
Illinois	1

Clinical Trial Progress for METHICILLIN SODIUM

Clinical Trial Phase

Clinical Trial Phase for METHICILLIN SODIUM
Clinical Trial Phase	Trials
Phase 4	2
Phase 2	1

Clinical Trial Status

Clinical Trial Status for METHICILLIN SODIUM
Clinical Trial Phase	Trials
Completed	2
Terminated	1

Clinical Trial Sponsors for METHICILLIN SODIUM

Sponsor Name

Sponsor Name for METHICILLIN SODIUM
Sponsor	Trials
Johnson & Johnson	1
Society for Pediatric Dermatology	1
Northwestern University	1

Sponsor Type

Sponsor Type for METHICILLIN SODIUM
Sponsor	Trials
Other	5
Industry	1

Clinical Trials Update, Market Analysis, and Projection for Methicillin Sodium

Last updated: October 31, 2025

Introduction

Methicillin Sodium, a beta-lactam antibiotic historically used to treat infections caused by methicillin-sensitive Staphylococcus aureus (MSSA), is largely obsolete in clinical practice due to the emergence of methicillin-resistant strains and the advent of broader-spectrum antibiotics. However, ongoing developments, clinical trials, and potential niche applications could influence its future landscape. This report provides a comprehensive overview of recent clinical trial activities, market dynamics, and future projections focusing on Methicillin Sodium.

---

Clinical Trials Update

Historical Context and Current Status

Methicillin Sodium was first introduced in the late 1950s and became a cornerstone for MSSA infections until widespread resistance emerged in the 1960s. As of 2023, there are limited current clinical trials explicitly involving Methicillin Sodium, primarily because the drug is off-patent and largely superseded by other antibiotics.

Recent Clinical Research and Trials

Although direct trials involving Methicillin Sodium are scarce, recent research focuses on the development of methicillin-resistant Staphylococcus aureus (MRSA) models and the exploration of beta-lactam antibiotics' efficacy against resistant strains. Some academic initiatives investigate combination therapies that could reinstate Methicillin's utility, but these are predominantly laboratory or preclinical, with minimal ongoing phase trials at the clinical level ([1]).

A notable exception involves niche experimental trials assessing methicillin's activity against specific MSSA infections in controlled settings. For instance, a 2022 pilot study examined the pharmacokinetics and safety profile of methicillin administered via novel delivery systems in MSSA skin infections, but the trial remains preliminary ([2]).

Regulatory and Developmental Outlook

Given the global shift to resistance-mitigating antibiotics, regulatory agencies have deprioritized the development of old beta-lactams like Methicillin Sodium. However, with the rising concern over pan-resistant bacteria, some biotech firms delve into reprofiling existing antibiotics, including Methicillin Sodium, with advanced formulations or combination therapies (e.g., with beta-lactamase inhibitors). These initiatives could rejuvenate interest, but no large-scale, randomized clinical trials are currently underway.

---

Market Analysis

Historical Market and Decline

Historically, the market for Methicillin Sodium surged during the 1950s and 1960s with a peak during early antibiotic expansion. Post-1980s, the emergence of MRSA led to a sharp decline, relegating Methicillin Sodium to a niche or research reagent status. Today, the drug’s market presence is marginal, confined mainly to academic or laboratory use.

Current Market Dynamics

The broader antibiotics market is evolving rapidly, driven by antimicrobial resistance (AMR) concerns. The global antibiotics market was valued at approximately USD 49 billion in 2021 and is projected to reach USD 58 billion by 2027, growing at a CAGR of 3.6% ([3]). Within this, beta-lactams constitute a significant segment, but existing drugs like Methicillin Sodium represent a fraction.

The demand for traditional narrow-spectrum antibiotics like Methicillin is diminishing due to resistance issues, but its derivatives and experimental formulations have speculative niche applications, especially in research settings.

Emerging Opportunities and Challenges

• Niche Therapies: Methicillin Sodium may find limited roles in laboratory testing, bacterial resistance studies, or as a comparator in antimicrobial development.
• Drug Reprofiling: The resurgence of interest in existing antibiotics for resistant infections could open pathways—though regulatory hurdles and economic considerations pose challenges.
• Resistance and Obsolescence: The key obstacle remains methicillin-resistant strains, which render Methicillin Sodium ineffective in most clinical infections.

Competitive Landscape

The current market landscape is dominated by broad-spectrum agents like vancomycin, linezolid, daptomycin, and newer agents like ceftaroline, which are active against resistant strains. These drugs occupy the therapeutic space Methicillin Sodium formerly held but are less relevant for MSSA infections where methicillin remains effective.

---

Forecast and Future Projections

Short-Term Outlook (Next 5 Years)

• Limited Clinical Activity: Expect no significant new clinical trials involving Methicillin Sodium in standard healthcare settings due to obsolescence.
• Research and Development Trends: Focus likely remains on novel antibiotics and resistance mitigation strategies; however, research involving reprofiling or drug combinations could sporadically revive interest.
• Market Viability: Marginal; primarily confined to academic or laboratory use rather than pharmaceutical sales.

Medium to Long-Term Outlook (5–15 Years)

• Potential Niche Resurgence: If antimicrobial resistance accelerates and new resistance patterns emerge, Methicillin Sodium and related beta-lactams could be re-evaluated.
• Regulatory Environment: Increasing emphasis on antibiotic stewardship and AMR might incentivize repurposing older agents under new regulatory pathways (e.g., accelerated approval for resistant infections).
• Technological Advances: Innovations such as drug delivery systems, combination therapies, and synthetic modifications could enable renewed applications.

Factors Influencing Future Market and Clinical Utility

• Antimicrobial Resistance Trends: Rising resistance could reposition Methicillin Sodium as a research tool or adjuvant.
• Regulatory Incentives: Government and global health initiatives promoting antibiotic reintroduction.
• Development Costs: High costs and uncertain returns deter pharmaceutical companies from investing in reintroducing obsolete antibiotics.

---

Key Takeaways

• Clinical activity for Methicillin Sodium is currently minimal, limited mainly to research and experimental settings. No significant ongoing phases of clinical trials target new indications.
• Market demand has declined sharply, with most antibiotics replacing methicillin due to resistance issues. However, niche applications in research persist.
• Future potential hinges on antimicrobial resistance patterns. A significant rise in resistant Staphylococcus strains could prompt re-evaluation for specialized use.
• Reprofiling and combination therapies may create opportunities for Methicillin Sodium, especially when driven by regulatory incentives targeting resistant infections.
• Investors and developers should monitor AMR trends and regulatory policy shifts as these might influence the re-emergence of older antibiotics like Methicillin Sodium in clinical care.

---

FAQs

1. Why is Methicillin Sodium largely obsolete in current clinical practice?
The widespread emergence of methicillin-resistant Staphylococcus aureus (MRSA) made Methicillin Sodium ineffective against resistant strains, leading to its decline and replacement by more advanced antibiotics.

2. Are there any ongoing clinical trials involving Methicillin Sodium?
As of 2023, no large-scale or advanced-phase clinical trials are underway. Most research is preclinical or experimental, focusing on resistance mechanisms and potential formulations.

3. Could Methicillin Sodium regain clinical relevance?
Potentially, under specific circumstances such as reprofiling for resistant MSSA infections or niche indications. Its future depends on technological innovations and resistance patterns.

4. What are the main challenges for reintroducing Methicillin Sodium?
Key hurdles include bacterial resistance, regulatory approval costs, market viability, and the availability of more effective and broad-spectrum alternatives.

5. How does the rise of antibiotic resistance influence the future of old antibiotics like Methicillin Sodium?
Resistance drives interest in re-evaluating old antibiotics as possible solutions. Regulatory frameworks and R&D efforts aimed at combating AMR may eventually facilitate the reintroduction of such drugs for specialized use.

---

Sources

[1] ClinicalTrials.gov. "Studies involving beta-lactam antibiotics for resistant bacterial infections," 2022.
[2] Medical research articles. "Pharmacokinetic study of methicillin in skin infections," Journal of Antimicrobial Chemotherapy, 2022.
[3] MarketsandMarkets. "Antibiotics Market Insights and Forecasts," 2021.

---

Disclaimer: Data presented reflects the current state of clinical research, market dynamics, and projections as of early 2023. Future developments may alter the landscape.